Rajeev Krishnadas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rajeev Krishnadas has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
Jonathan Cavanagh
Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom; Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, United Kingdom
15 shared publicationsJohn McLean
Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, UK
8 shared publications- Samuel Paul Leighton
University of Glasgow
7 shared publications - Jonathan Cavanagh
School of Infection & Immunity, University of Glasgow; Glasgow, United Kingdom
6 shared publications Alex McConnachie
Robertson Centre for Biostatistics, University of Glasgow, Glasgow, Scotland, UK
5 shared publicationsChris J. Packard
Glasgow Clinical Research Facility, Glasgow, Scotland, UK
5 shared publications
Latest Publications
- Open Access
The Antipsychotic Load (AP_Load2026): a normalised prescribed-dose index for schizophrenia research
Background and Hypothesis Schizophrenia research routinely reduces antipsychotic treatment to a single number, but the available summaries disagree. Chlorpromazine equivalents, the WHO Defined Daily Dose (DDD) and the percentage of the licensed maximum (%BNFmax) rank the same patient differently, most of all for clozapine, whose dose-concentration relationship varies several-fold with sex and smoking. We hypothesised that referencing clozapine dose to a target individualised for sex and smoking would track plasma clozapine better than dose-proportional measures. Study Design In the Antipsychotic Load (AP_Load2026), each daily dose is expressed as a percentage of a reference dose, summed without a cap. Clozapine is referenced to a target individualised for sex and cigarettes per day, under two published anchor schemes, and other antipsychotics to a dose reconciling the WHO DDD and the licensed maximum. The clozapine term was tested against plasma clozapine (1316 assessments, 255 patients) with log-log mixed-effects models, and the non-clozapine reference against independently derived published doses. Study Results The individualised reference tracked plasma clozapine better than any dose-proportional measure (marginal R^2 0.249 vs. 0.166; deltaR^2 0.082, 95% CI 0.044-0.120). The scheme with the larger smoking correction fitted better (0.249 vs. 0.231), an ordering robust to quality-control variants and co-prescription. Of five candidate references for other antipsychotics, %BNFmax was the least consistent with external criteria. Conclusions AP_Load2026 is a transparent framework for normalising prescribed antipsychotic dose. Its clozapine reference is validated against a biomarker, whereas the reference for other antipsychotics is a calibrated convention at least comparable with existing alternatives. The index is particularly suited to treatment-resistant and clozapine-enriched cohorts.
Open AccessThe Antipsychotic Load (AP_Load2026): a normalised prescribed-dose index for schizophrenia research
Background and Hypothesis Schizophrenia research routinely reduces antipsychotic treatment to a single number, but the available summaries disagree. Chlorpromazine equivalents, the WHO Defined Daily Dose (DDD) and the percentage of the licensed maximum (%BNFmax) rank the same patient differently, most of all for clozapine, whose dose-concentration relationship varies several-fold with sex and smoking. We hypothesised that referencing clozapine dose to a target individualised for sex and smoking would track plasma clozapine better than dose-proportional measures. Study Design In the Antipsychotic Load (AP_Load2026), each daily dose is expressed as a percentage of a reference dose, summed without a cap. Clozapine is referenced to a target individualised for sex and cigarettes per day, under two published anchor schemes, and other antipsychotics to a dose reconciling the WHO DDD and the licensed maximum. The clozapine term was tested against plasma clozapine (1316 assessments, 255 patients) with log-log mixed-effects models, and the non-clozapine reference against independently derived published doses. Study Results The individualised reference tracked plasma clozapine better than any dose-proportional measure (marginal R^2 0.249 vs. 0.166; deltaR^2 0.082, 95% CI 0.044-0.120). The scheme with the larger smoking correction fitted better (0.249 vs. 0.231), an ordering robust to quality-control variants and co-prescription. Of five candidate references for other antipsychotics, %BNFmax was the least consistent with external criteria. Conclusions AP_Load2026 is a transparent framework for normalising prescribed antipsychotic dose. Its clozapine reference is validated against a biomarker, whereas the reference for other antipsychotics is a calibrated convention at least comparable with existing alternatives. The index is particularly suited to treatment-resistant and clozapine-enriched cohorts.
- Open Access
- 25 September 2026
- Published by SAGE Publications in Journal of Psychopharmacology
Early intervention with clozapine: Is there a neurobiological critical period for treatment-resistant schizophrenia?
Clozapine is the most effective treatment for treatment-resistant schizophrenia, yet it is often introduced late. This article proposes a critical period hypothesis, arguing that clozapine is most effective when started during a stage of illness in which network plasticity and synaptic substrate are still partially preserved. We outline a neurobiological continuum from first-line antipsychotic response to ultra-treatment resistance, emphasising dynamic changes in dopamine, glutamate, gamma-aminobutyric acid and muscarinic cholinergic systems. Observational studies suggest that earlier clozapine initiation is associated with better outcomes, particularly for negative symptoms and functioning. The hypothesis supports earlier recognition of treatment resistance and reduced avoidable delay.
- 25 September 2026
- Published by SAGE Publications in Journal of Psychopharmacology
Open AccessEarly intervention with clozapine: Is there a neurobiological critical period for treatment-resistant schizophrenia?
Clozapine is the most effective treatment for treatment-resistant schizophrenia, yet it is often introduced late. This article proposes a critical period hypothesis, arguing that clozapine is most effective when started during a stage of illness in which network plasticity and synaptic substrate are still partially preserved. We outline a neurobiological continuum from first-line antipsychotic response to ultra-treatment resistance, emphasising dynamic changes in dopamine, glutamate, gamma-aminobutyric acid and muscarinic cholinergic systems. Observational studies suggest that earlier clozapine initiation is associated with better outcomes, particularly for negative symptoms and functioning. The hypothesis supports earlier recognition of treatment resistance and reduced avoidable delay.
- Open Access
- 10 August 2026
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 12 (5) , e213
Causes of death and mortality patterns in clozapine-treated patients: 17-year retrospective cohort study
Background: Clozapine reduces overall mortality and suicide risk in schizophrenia, but the specific causes and clinical contexts of death among clozapine-treated patients remain less well characterised. Aims: We aimed to characterise causes of death in clozapine-treated patients within a defined UK catchment area over 17 years (2009–2025); compare features across predefined mortality clusters (suicide, expected, unexpected); compare unexpected death cases with a clozapine-treated comparison cohort alive in 2019 and examine temporal mortality patterns. Method: We conducted a retrospective, descriptive cohort study of all deaths among clozapine-treated patients within a UK mental health National Health Service Trust between 1 January 2009 and 31 December 2025. Deaths were classified into suicide, expected and non-intentional unexpected, using a previously established framework. Variables were compared across clusters and between unexpected death cases and a clozapine-treated comparison cohort alive in 2019. Results: Of 87 deaths, 11 (12.6%) were suicides, 29 (33.3%) were expected and 47 (54.0%) were non-intentional unexpected. Malignancy was the most common cause (21/87, 24.1%), followed by cardiovascular (13/87, 14.9%) and respiratory or infective causes (9/87, 10.3%). Age differed across clusters ( p = 0.005), with suicides at younger ages. Compared with the 2019 cohort, patients who died unexpectedly were older (55.0 v . 48.6 years, p = 0.006) and more likely to smoke (75.0 v . 34.6%, p < 0.001). Annual mortality peaked in 2021 and was not fully explained by direct COVID-19 deaths. Conclusions: Mortality in clozapine-treated patients arises across diverse clinical contexts, with more than half classified as non-intentional unexpected. Findings support sustained physical health monitoring, closer attention to smoking and other modifiable risks, and continuity of care.
- 10 August 2026
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 12 (5) , e213
Open AccessCauses of death and mortality patterns in clozapine-treated patients: 17-year retrospective cohort study
Background: Clozapine reduces overall mortality and suicide risk in schizophrenia, but the specific causes and clinical contexts of death among clozapine-treated patients remain less well characterised. Aims: We aimed to characterise causes of death in clozapine-treated patients within a defined UK catchment area over 17 years (2009–2025); compare features across predefined mortality clusters (suicide, expected, unexpected); compare unexpected death cases with a clozapine-treated comparison cohort alive in 2019 and examine temporal mortality patterns. Method: We conducted a retrospective, descriptive cohort study of all deaths among clozapine-treated patients within a UK mental health National Health Service Trust between 1 January 2009 and 31 December 2025. Deaths were classified into suicide, expected and non-intentional unexpected, using a previously established framework. Variables were compared across clusters and between unexpected death cases and a clozapine-treated comparison cohort alive in 2019. Results: Of 87 deaths, 11 (12.6%) were suicides, 29 (33.3%) were expected and 47 (54.0%) were non-intentional unexpected. Malignancy was the most common cause (21/87, 24.1%), followed by cardiovascular (13/87, 14.9%) and respiratory or infective causes (9/87, 10.3%). Age differed across clusters ( p = 0.005), with suicides at younger ages. Compared with the 2019 cohort, patients who died unexpectedly were older (55.0 v . 48.6 years, p = 0.006) and more likely to smoke (75.0 v . 34.6%, p < 0.001). Annual mortality peaked in 2021 and was not fully explained by direct COVID-19 deaths. Conclusions: Mortality in clozapine-treated patients arises across diverse clinical contexts, with more than half classified as non-intentional unexpected. Findings support sustained physical health monitoring, closer attention to smoking and other modifiable risks, and continuity of care.
- Open Access
- 30 April 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 229 (4) , 1
The Precision Psychiatry Imperative: Response to Seyedsalehi et al – ERRATUM
- 30 April 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 229 (4) , 1
Open AccessThe Precision Psychiatry Imperative: Response to Seyedsalehi et al – ERRATUM
- 7 April 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 229 (4) , 1-2
The Precision Psychiatry Imperative: Response to Seyedsalehi et al
- 7 April 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 229 (4) , 1-2
The Precision Psychiatry Imperative: Response to Seyedsalehi et al
- Open Access
- 29 March 2026
- Published by Wiley in Advanced Science
- Vol. 13 (37) , e19049
Autoimmune Encephalitis in Acute Care—Pathology, Diagnosis, and Management
Autoimmune encephalitis (AE) is characterized by immune‐mediated inflammation of the brain parenchyma, presenting with various neurological syndromes, including but not limited to seizures, altered consciousness, neuropsychiatric symptoms, and movement disorders. A significant proportion of patients with AE develop life‐threatening complications that require hospital and potentially ICU admission. These patients present unique diagnostic and therapeutic challenges, presenting with a range of neurological emergencies such as refractory status epilepticus, severe dysautonomia, coma, and respiratory failure. Diagnosis relies on a combination of clinical criteria, detection of autoantibodies in serum and cerebrospinal fluid, neuroimaging, and electroencephalography, though antibody‐negative AE poses considerable diagnostic difficulty. Management is centered on prompt initiation of first‐line immunotherapies (corticosteroids, plasma exchange, and intravenous immunoglobulin therapy) and escalation to second‐line or emerging targeted therapies (e.g., rituximab, cyclophosphamide, IL‐6 inhibitors, proteasome inhibitors) in refractory cases, alongside aggressive supportive care for neurological and systemic complications. The prognosis is variable and influenced by factors such as the specific autoantibody, the timeliness of treatment, and the severity of complications. Long‐term sequelae, including cognitive and psychiatric impairments, are common among survivors. This review provides a synthesis of current knowledge on AE in acute and intensive care. Given these diagnostic challenges and the potential for severe symptom presentation, the authors believe that this review is an essential addition to the discourse. This review covers pathophysiology, epidemiology, clinical manifestations, diagnostic approaches, immunotherapeutic strategies, management of critical complications, syndrome‐specific considerations, prognostication, intensive care unit‐related complications, and future research priorities to support optimal care.
- 29 March 2026
- Published by Wiley in Advanced Science
- Vol. 13 (37) , e19049
Open AccessAutoimmune Encephalitis in Acute Care—Pathology, Diagnosis, and Management
Autoimmune encephalitis (AE) is characterized by immune‐mediated inflammation of the brain parenchyma, presenting with various neurological syndromes, including but not limited to seizures, altered consciousness, neuropsychiatric symptoms, and movement disorders. A significant proportion of patients with AE develop life‐threatening complications that require hospital and potentially ICU admission. These patients present unique diagnostic and therapeutic challenges, presenting with a range of neurological emergencies such as refractory status epilepticus, severe dysautonomia, coma, and respiratory failure. Diagnosis relies on a combination of clinical criteria, detection of autoantibodies in serum and cerebrospinal fluid, neuroimaging, and electroencephalography, though antibody‐negative AE poses considerable diagnostic difficulty. Management is centered on prompt initiation of first‐line immunotherapies (corticosteroids, plasma exchange, and intravenous immunoglobulin therapy) and escalation to second‐line or emerging targeted therapies (e.g., rituximab, cyclophosphamide, IL‐6 inhibitors, proteasome inhibitors) in refractory cases, alongside aggressive supportive care for neurological and systemic complications. The prognosis is variable and influenced by factors such as the specific autoantibody, the timeliness of treatment, and the severity of complications. Long‐term sequelae, including cognitive and psychiatric impairments, are common among survivors. This review provides a synthesis of current knowledge on AE in acute and intensive care. Given these diagnostic challenges and the potential for severe symptom presentation, the authors believe that this review is an essential addition to the discourse. This review covers pathophysiology, epidemiology, clinical manifestations, diagnostic approaches, immunotherapeutic strategies, management of critical complications, syndrome‐specific considerations, prognostication, intensive care unit‐related complications, and future research priorities to support optimal care.
- Open Access
- 9 March 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-10
Antipsychotic-induced weight gain in psychosis: causal mediation analysis and feasibility study of causal actionable prediction model development using counterfactuals to target obesity
Background: People with psychosis have a life expectancy that is reduced by 15 years, mainly owing to preventable physical illnesses of which obesity is a precursor. Obesity is three times more common in individuals with psychosis, and antipsychotics are an important cause. Prediction could individualise obesity treatment, but current models are not fully actionable for individuals. Aims: To test whether antipsychotic-induced weight increase at 1 year is causally mediated by weight change in the first 12 weeks of treatment, and then develop and internally validate a causal actionable prediction pathway to prevent antipsychotic-induced obesity. Method: This was a post hoc analysis of a clinical trial of olanzapine versus haloperidol which recruited 263 participants with first-episode psychosis. We conducted two distinct analyses: causal mediation and prediction modelling, within which there were two sequential models (a baseline model to predict 12-week outcome and a 12-week model to predict 1-year outcome), followed by counterfactual prediction. In the first analysis, we used parallel causal mediation analysis to determine the natural direct and indirect and total effects of antipsychotic choice on weight in 97 participants, considering two mediators: weight change from 0 to 12 weeks, and weight change from 12 to 52 weeks. In the second analysis, we first developed a baseline causal actionable prediction model to predict weight gain at 12 weeks in 172 participants and then a 12-week model to predict obesity at 1 year in 97 of the participants. Finally, we demonstrated counterfactual prediction. Results: Antipsychotic-induced weight gain at 1 year appeared to be causally mediated by weight change during the first 12 weeks of treatment (indirect effect 5.70; 95% CI 2.83 to 8.66). At internal validation, the discrimination c-statistic for the baseline causal actionable prediction model was 0.728 (95% CI 0.661 to 0.801), and the calibration slope was 0.768 (95% CI 0.436 to 1.21). For the 12-week model, the c-statistic was 0.904 (95% CI 0.820 to 0.961), and the calibration slope was 0.601 (95% CI −0.0633 to 1.21). We used the models to predict the counterfactual outcomes of antipsychotic choice and 12-week weight change. Conclusions: Our results show that it may be early rather than later weight change that causally mediates antipsychotic-induced weight gain at 1 year. They also demonstrate the potential for causal actionable prediction of counterfactuals for true precision medicine, although this is tempered by the feasibility scope of this study and small sample size. Our results are hypothesis-generating and not yet clinically deployable.
- 9 March 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-10
Open AccessAntipsychotic-induced weight gain in psychosis: causal mediation analysis and feasibility study of causal actionable prediction model development using counterfactuals to target obesity
Background: People with psychosis have a life expectancy that is reduced by 15 years, mainly owing to preventable physical illnesses of which obesity is a precursor. Obesity is three times more common in individuals with psychosis, and antipsychotics are an important cause. Prediction could individualise obesity treatment, but current models are not fully actionable for individuals. Aims: To test whether antipsychotic-induced weight increase at 1 year is causally mediated by weight change in the first 12 weeks of treatment, and then develop and internally validate a causal actionable prediction pathway to prevent antipsychotic-induced obesity. Method: This was a post hoc analysis of a clinical trial of olanzapine versus haloperidol which recruited 263 participants with first-episode psychosis. We conducted two distinct analyses: causal mediation and prediction modelling, within which there were two sequential models (a baseline model to predict 12-week outcome and a 12-week model to predict 1-year outcome), followed by counterfactual prediction. In the first analysis, we used parallel causal mediation analysis to determine the natural direct and indirect and total effects of antipsychotic choice on weight in 97 participants, considering two mediators: weight change from 0 to 12 weeks, and weight change from 12 to 52 weeks. In the second analysis, we first developed a baseline causal actionable prediction model to predict weight gain at 12 weeks in 172 participants and then a 12-week model to predict obesity at 1 year in 97 of the participants. Finally, we demonstrated counterfactual prediction. Results: Antipsychotic-induced weight gain at 1 year appeared to be causally mediated by weight change during the first 12 weeks of treatment (indirect effect 5.70; 95% CI 2.83 to 8.66). At internal validation, the discrimination c-statistic for the baseline causal actionable prediction model was 0.728 (95% CI 0.661 to 0.801), and the calibration slope was 0.768 (95% CI 0.436 to 1.21). For the 12-week model, the c-statistic was 0.904 (95% CI 0.820 to 0.961), and the calibration slope was 0.601 (95% CI −0.0633 to 1.21). We used the models to predict the counterfactual outcomes of antipsychotic choice and 12-week weight change. Conclusions: Our results show that it may be early rather than later weight change that causally mediates antipsychotic-induced weight gain at 1 year. They also demonstrate the potential for causal actionable prediction of counterfactuals for true precision medicine, although this is tempered by the feasibility scope of this study and small sample size. Our results are hypothesis-generating and not yet clinically deployable.
- 30 December 2025
- Published by BMJ in BMJ Innovations
- Vol. 12 (1) , 28-33
Improving access to clozapine: a virtual ward model for community-based initiation
Treatment-resistant schizophrenia (TRS) poses significant challenges. Clozapine, the most effective antipsychotic for TRS, is underused due to its side effect profile and intensive monitoring requirements during initiation. This article describes a collaborative virtual ward model in Peterborough, UK, for community-based clozapine initiation. Integrating wearable technology for real-time health tracking with video consultations, the service provides hospital-equivalent care at home. A partnership between Cambridgeshire and Peterborough NHS Foundation Trust and North West Anglia NHS Foundation Trust merges mental health expertise with acute care infrastructure. Early experiences suggest higher patient engagement, increased clinician confidence and reduced inpatient burden. This initiative has the potential to transform clozapine access, bridge physical and mental health services and offer a blueprint for patient-centred TRS care.
- 30 December 2025
- Published by BMJ in BMJ Innovations
- Vol. 12 (1) , 28-33
Improving access to clozapine: a virtual ward model for community-based initiation
Treatment-resistant schizophrenia (TRS) poses significant challenges. Clozapine, the most effective antipsychotic for TRS, is underused due to its side effect profile and intensive monitoring requirements during initiation. This article describes a collaborative virtual ward model in Peterborough, UK, for community-based clozapine initiation. Integrating wearable technology for real-time health tracking with video consultations, the service provides hospital-equivalent care at home. A partnership between Cambridgeshire and Peterborough NHS Foundation Trust and North West Anglia NHS Foundation Trust merges mental health expertise with acute care infrastructure. Early experiences suggest higher patient engagement, increased clinician confidence and reduced inpatient burden. This initiative has the potential to transform clozapine access, bridge physical and mental health services and offer a blueprint for patient-centred TRS care.
- Open Access
- 4 December 2025
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 32 (5) , 1-13
Navigating the new frontier: psychiatrist’s guide to using large language models in daily practice
SUMMARY: Large language models (LLMs) like OpenAI’s ChatGPT, Google’s Gemini and Anthropic’s Claude can be useful tools in psychiatric practice, helping with tasks such as searching for information, managing administrative work and supporting education. This article demystifies how these tools work by explaining their core operational principles and noting their key limitations, including the risks of confabulation (fabricating information), sycophancy and knowledge cut-offs. It provides practical guidance on mitigating these risks through structured ‘prompt engineering’ and offers a safety framework for integrating LLMs into low-risk administrative and educational workflows. The article stresses the importance of approaching these technologies with caution by independently verifying information, adhering to UK data protection laws and upholding the principles of best practice in patient care. The goal is to help clinicians use these powerful but fallible technologies wisely, ensuring that patient safety and professional responsibility remain paramount as they explore these new tools.
- 4 December 2025
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 32 (5) , 1-13
Open AccessNavigating the new frontier: psychiatrist’s guide to using large language models in daily practice
SUMMARY: Large language models (LLMs) like OpenAI’s ChatGPT, Google’s Gemini and Anthropic’s Claude can be useful tools in psychiatric practice, helping with tasks such as searching for information, managing administrative work and supporting education. This article demystifies how these tools work by explaining their core operational principles and noting their key limitations, including the risks of confabulation (fabricating information), sycophancy and knowledge cut-offs. It provides practical guidance on mitigating these risks through structured ‘prompt engineering’ and offers a safety framework for integrating LLMs into low-risk administrative and educational workflows. The article stresses the importance of approaching these technologies with caution by independently verifying information, adhering to UK data protection laws and upholding the principles of best practice in patient care. The goal is to help clinicians use these powerful but fallible technologies wisely, ensuring that patient safety and professional responsibility remain paramount as they explore these new tools.